GENELUX-Final-Logo-Notagline.png
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
September 03, 2024 16:01 ET | Genelux Corporation
WESTLAKE VILLAGE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President,...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates
August 14, 2024 16:05 ET | Genelux Corporation
WESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2024
July 30, 2024 07:00 ET | Genelux Corporation
WESTLAKE VILLAGE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
May 24, 2024 08:00 ET | Genelux Corporation
Genelux Corporation Announces Pricing of Approximately $27.5 Million Underwritten Offering of Common Stock and Accompanying Warrants
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
May 23, 2024 16:01 ET | Genelux Corporation
Genelux Corporation Announces Proposed Public Offering of Common Stock and Warrants
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
May 09, 2024 16:25 ET | Genelux Corporation
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
April 01, 2024 07:00 ET | Genelux Corporation
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
November 27, 2023 07:00 ET | Genelux Corporation
Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates
November 14, 2023 17:50 ET | Genelux Corporation
- Expanded executive team as Lourie Zak appointed Chief Financial Officer -  - Extended clinical focus on systemic administration in small cell lung cancer - - $29.9 million in cash and equivalents...
GENELUX-Final-Logo-Notagline.png
Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 14, 2023 07:00 ET | Genelux Corporation
WESTLAKE VILLAGE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that on September 11, 2023, the...